Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

This study has been terminated.
(Low recruitment due to change in standard of care)
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research Identifier:
First received: March 8, 2013
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)